ICU Medical : Q1 2025 ICU Medical Earnings Call Presentation 5825 (Final) (002)

Published: 2025-05-08 20:08:42 ET ICUI

Published on 05/08/2025 at 20:08

‌ICU Medical, Inc

Q1 2025 Conference Call Presentation

May 8, 2025

‌Disclosures

Any statement concerning Management's expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results.

Future results are subject to risks and uncertainties, including the risk factors described in the Company's filings with the Securities and Exchange Commission, which include those in the most recent Form 10-K and subsequent filings. Actual results in the future may differ materially from Management's current expectations.

These forward-looking statements, including statements about tariffs, the timing and resolution of Warning Letters received from the FDA, the anticipated benefits and costs associated with the close of the transaction with the JV (as defined below), inflation levels, interest rates, global public health crises and other geopolitical events, are made based upon our current expectations and we undertake no duty to update information provided in this presentation.

In addition to the financial measures prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), this presentation contains certain non-GAAP financial measures, such as Adjusted EBITDA, adjusted diluted earnings per share ("EPS"), and financial measures presented on a constant currency. Our non-GAAP revenue presented on a constant currency basis uses the average exchange rate for revenues from the prior year applied to the current year results.

Certain guidance in this presentation excludes the potential impact from the Company's previously announced joint venture with Otsuka Pharmaceutical Factory America, Inc. (the "JV" and, the related transaction, the "JV Transaction"). To facilitate a greater understanding of the expected impact of the JV Transaction on the Company's fiscal year 2025 guidance, this presentation also includes estimated impacts from the JV Transaction and the effect of those impacts on the Company's fiscal year 2025 guidance. The estimated impacts are not intended to represent pro forma financial statements prepared in accordance with GAAP or Regulation S-X and do not reflect all other adjustments for costs or other expenses, cost savings or synergies that may be achieved. Reconciliations of the Company's Adjusted EBITDA and Adjusted diluted EPS after giving effect to the estimated impacts of the JV Transaction to the most directly comparable GAAP financial measures cannot be provided without unreasonable efforts and are not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations and certain other items reflected in our reconciliation of historical Adjusted EBITDA and Adjusted diluted earnings per share, the amounts of which could be material. See slide 4 for additional information.

These non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods.

‌2024 - 2025 Adjusted Revenue

In $ Millions

LVP Infusion

Ambulatory

Syringe

Tracheostomy

Vascular Access

Oncology

Infusion Therapy

Pain Kits

Warming

Anesthesia & Resp

Critical Care

2024

Total

2025

Consumables

YoY Growth YoY Growth (FXN)

244

262

265

268

1,039

266

10%

11%

10%

Systems

YoY Growth YoY Growth (FXN)

157

164

160

172

652

166

-3%

11%

10%

Vital Care

YoY Growth

YoY Growth (FXN)

151

156

155

182

644

167

-4%

16%

10%

-4%

16%

11%

Total ICU

553

581

580

622

2,335

599

YoY Growth

-1%

YoY Growth (FXN)

10%

Solutions

Vital Care

Infusion Systems

Consumables

Amounts may not foot due to rounding.

‌2025 Guidance and Modeling Assumptions

In $ Millions, except per share amounts

Disclaimer

ICU Medical Inc. published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 22:34 UTC.